胎儿和新生儿同种免疫性血小板减少症:基于证据实践的国际建议
国际专家组针对胎儿和新生儿同种免疫性血小板减少症(FNAIT)的产前管理、产后管理、诊断检测和普遍筛查制定循证建议。为确认FNAIT,当父亲未知、不可检测或为涉及抗原杂合子时,应在妊娠期采用非侵入性方法(如质量有保证)进行胎儿人类血小板抗原(HPA)分型。既往有FNAIT相关颅内出血(ICH)患儿的女性,在后续受累妊娠中应尽早于孕12周开始接受静脉注射免疫球蛋白(IVIG)输注。
要点
- 既往有FNAIT相关ICH患儿的女性,后续受累妊娠应尽早于孕12周开始IVIG输注。
- 为确认FNAIT,当父亲未知、不可检测或为涉及抗原杂合子时,应在妊娠期行胎儿HPA分型,采用非侵入性方法(如质量有保证)。
- 理想情况下,分娩时应备有HPA选择血小板供可能受累新生儿使用,以按需提升新生儿血小板计数;若无法立即获得,应输注非选择血小板。
核心结论
- 为确认FNAIT,当父亲未知、不可检测或为涉及抗原杂合子时,应在妊娠期行胎儿HPA分型,采用非侵入性方法(如质量有保证)。
- 既往有FNAIT相关ICH患儿的女性,在后续受累妊娠中应尽早于孕12周开始IVIG输注。
- 理想情况下,分娩时应备有HPA选择血小板供可能受累新生儿使用,以按需提升新生儿血小板计数;若HPA选择血小板无法立即获得,应输注非选择血小板。
研究设计与样本
- 国际专家组采用严谨方法检索、审查已发表数据,针对产前管理、产后管理、诊断检测和普遍筛查制定循证建议。
关键数值与推荐
- 为确认FNAIT,当父亲未知、不可检测或为涉及抗原杂合子时,应在妊娠期行胎儿HPA分型,采用非侵入性方法(如质量有保证)。
- 既往有FNAIT相关ICH患儿的女性,在后续受累妊娠中应尽早于孕12周开始IVIG输注。
- 理想情况下,分娩时应备有HPA选择血小板供可能受累新生儿使用,以按需提升新生儿血小板计数;若HPA选择血小板无法立即获得,应输注非选择血小板。
临床怎么用
- 为确认FNAIT,当父亲未知、不可检测或为涉及抗原杂合子时,应在妊娠期行胎儿HPA分型,采用非侵入性方法(如质量有保证)。
- 既往有FNAIT相关ICH患儿的女性,在后续受累妊娠中应尽早于孕12周开始IVIG输注。
- 理想情况下,分娩时应备有HPA选择血小板供可能受累新生儿使用,以按需提升新生儿血小板计数;若HPA选择血小板无法立即获得,应输注非选择血小板。
局限性
- 需要开展FNAIT研究以优化产前和产后管理、开发风险分层算法以指导管理并标准化实验室检测以识别高危妊娠。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) may result in severe bleeding, particularly fetal and neonatal intracranial haemorrhage (ICH). As a result, FNAIT requires prompt identification and treatment; subsequent pregnancies need close surveillance and management. An international panel convened to develop evidence-based recommendations for diagnosis and management of FNAIT. A rigorous approach was used to search, review and develop recommendations from published data for: antenatal management, postnatal management, diagnostic testing and universal screening. To confirm FNAIT, fetal human platelet antigen (HPA) typing, using non-invasive methods if quality-assured, should be performed during pregnancy when the father is unknown, unavailable for testing or heterozygous for the implicated antigen. Women with a previous child with an ICH related to FNAIT should be offered intravenous immunoglobulin (IVIG) infusions during subsequent affected pregnancies as early as 12 weeks gestation. Ideally, HPA-selected platelets should be available at delivery for potentially affected infants and used to increase the neonatal platelet count as needed. If HPA-selected platelets are not immediately available, unselected platelets should be transfused. FNAIT studies that optimize antenatal and postnatal management, develop risk stratification algorithms to guide management and standardize laboratory testing to identify high risk pregnancies are needed.
引用
- Lieberman L, Greinacher A, Murphy MF, et al. Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. Br J Haematol. 2019. PMID: 30828796. doi:10.1111/bjh.15813
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。